Moderna Inc. ($MRNA) Stock Forecast: Up 5.2% Today

What is Moderna Inc.?

Moderna (NASDAQ: MRNA) is a leading biotechnology company focusing on innovative mRNA technology for vaccines and therapies, showing a strong market performance today.

Why is Moderna Inc. going up?

MRNA stock is up 5.2% on Jun 12, 2026 13:51

• Moderna's stock rose nearly 8%, in line with Nasdaq's recovery and positive market sentiment.
• Investor interest is high in Moderna's mRNA cancer vaccine pipeline, particularly with the approval of a new trial for mRNA-4194 in Lynch syndrome patients by UK regulators.
• Analysts are recommending a "Hold" on Moderna despite the stock's rise, with an average target price lower than the current closing value.
• The upswing in Moderna's stock may also be linked to a legal conflict with BioNTech regarding patent infringement, with Moderna asserting that its new COVID-19 vaccine does not infringe upon BioNTech's intellectual property, adding an intriguing element to the stock's movement.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

SmartHarvest Portfolios LLC Buys Shares of 9,927 AbbVie Inc. $ABBV

SmartHarvest Portfolios LLC has acquired 9,927 shares of AbbVie Inc. (NYSE:ABBV), valued at approximately $2.27 million, making it their 18th largest holding. This move is part of a broader trend of institutional investors like Vanguard, Geode Capital Management, and Norges Bank increasing their stakes in AbbVie, bringing total institutional ownership to over 70%. Despite a recent FDA Complete Response Letter for TrenibotE due to manufacturing issues, analyst sentiment remains largely positive, citing strong growth drivers in Skyrizi and Rinvoq and several price target increases.

https://www.marketbeat.com/instant-alerts/filing-smartharvest-portfolios-llc-buys-shares-of-9927-abbvie-inc-abbv-2026-06-12/

Argenx SE Stock (NL0010832176): Biotech name in focus amid sector headwinds

Argenx SE, a European biotech company, is under investor scrutiny due to its growing autoimmune-drug sales despite broader sector valuation pressures. The company's stock trades below its 52-week high, reflecting sector-wide headwinds like higher interest rates and a shift away from growth-oriented biotechs. Argenx is positioned as a diversified biotech, with its commercial autoimmune franchise and pipeline providing a more stable growth story compared to some other volatile biotech firms.

https://www.ad-hoc-news.de/boerse/news/ueberblick/argenx-se-stock-nl0010832176-biotech-name-in-focus-amid-sector/69524487

Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus

Moderna (NASDAQ: MRNA) shares rose nearly 8% following a strong Nasdaq recovery, closing at $49.64. The bounce occurred amidst positive market sentiment and without specific company news, though investor focus remains on Moderna's mRNA cancer vaccine pipeline, particularly after UK regulators approved a new trial for its experimental mRNA-4194 in Lynch syndrome patients. Despite the stock's gains, analysts generally maintain a "Hold" rating with an average target price below the current close.

https://ts2.tech/en/moderna-gains-almost-8-with-nasdaq-recovery-cancer-vaccine-pipeline-still-a-key-focus/

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Zenas BioPharma will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, with the presentation available on-demand starting June 15, 2026. The company is a clinical-stage global biopharmaceutical firm focused on developing transformative therapies for autoimmune diseases, including two late-stage potential franchise molecules, obexelimab and orelabrutinib. Zenas is also advancing several earlier-stage programs targeting various immune pathways.

https://ca.finance.yahoo.com/news/zenas-biopharma-present-h-c-201500057.html

Moderna Says New COVID Vax Doesn't Infringe BioNTech IP

Moderna has responded to BioNTech's patent infringement lawsuit, asserting that its newer COVID-19 vaccine does not exploit BioNTech's technology and challenging the validity of BioNTech's patent. This legal battle centers on claims that Moderna's vaccine infringes upon intellectual property related to BioNTech's own COVID-19 vaccine. Moderna maintains its innocence and contests the foundational legitimacy of the patent in question.

https://www.law360.com/articles/2488379/moderna-says-new-covid-vax-doesn-t-infringe-biontech-ip

Trending Today

Pinterest Inc. Class A ($PINS) Stock Forecast: Down 6.1% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 5.1% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 5.1% Today

Teradyne, Inc. ($TER) Stock Forecast: Up 7.0% Today

Albemarle Corporation ($ALB) Stock Forecast: Up 8.1% Today

Fox Corporation ($FOXA) Stock Forecast: Down 4.6% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 89.5% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.3% Today

Mosaic Company (The) ($MOS) Stock Forecast: Up 8.5% Today

TKO Group Holdings Inc ($TKO) Stock Forecast: Down 5.2% Today

Moderna Inc. Price History

12.05.2026 - MRNA Stock was up 5.2%

• Moderna's stock rose nearly 8%, in line with Nasdaq's recovery and positive market sentiment.
• Investor interest is high in Moderna's mRNA cancer vaccine pipeline, particularly with the approval of a new trial for mRNA-4194 in Lynch syndrome patients by UK regulators.
• Analysts are recommending a "Hold" on Moderna despite the stock's rise, with an average target price lower than the current closing value.
• The upswing in Moderna's stock may also be linked to a legal conflict with BioNTech regarding patent infringement, with Moderna asserting that its new COVID-19 vaccine does not infringe upon BioNTech's intellectual property, adding an intriguing element to the stock's movement.

03.05.2026 - MRNA Stock was up 7.8%

• Moderna's shares surged by 8.1% today due to positive updates, including encouraging data on a new cancer vaccine, an expanded partnership for an ebolavirus vaccine, and the launch of an e-commerce platform.
• The bullish momentum was reinforced by UBS increasing its price target for Moderna, Inc. (MRNA) in anticipation of key pipeline catalysts, reflecting confidence in the company's future.
• Despite facing scrutiny over allegations regarding the efficacy of its RSV vaccine, investors appeared more focused on the positive developments and growth opportunities in the oncology market.
• Anticipated growth in the Acute Respiratory Distress Syndrome (ARDS) market and ongoing research by industry leaders likely contributed to the positive sentiment surrounding Moderna and its mRNA technology.

03.05.2026 - MRNA Stock was up 5.5%

• Moderna (MRNA) saw a significant uptrend recently due to various factors:
• Bright prospects in the Acute Respiratory Distress Syndrome (ARDS) market, with growth projections fueled by innovative therapies being researched, potentially aligning with Moderna's unique vaccine development strategies.
• Improved valuation by UBS before key pipeline events, reflecting confidence in Moderna's future and growth potential.
• Despite ongoing challenges, optimism among investors remains high regarding Moderna's upcoming projects and regulatory milestones.
• Favorable industry sentiment in healthcare, particularly in fields like oncology and acute pain management, may have influenced the positive movement in Moderna's stock.

04.05.2026 - MRNA Stock was up 9.7%

• Moderna's stock saw a 7.49% increase as investors look forward to upcoming events, such as its involvement in crucial healthcare conferences and the release of encouraging data on its melanoma treatment.
• Optimism has been reignited around Moderna's partnership with Merck for the melanoma vaccine program, showing consistent enhancements in survival rates, fueling the stock's surge.
• The President of Moderna exercising restricted stock units (RSUs), coupled with favorable updates on the company's oncology pipeline extending beyond COVID vaccines, likely bolstered bullish sentiment, propelling the stock upward today.

04.05.2026 - MRNA Stock was up 9.2%

• Moderna's stock saw a notable increase today after a period of declines, as investors are eagerly awaiting important updates from the company.
• Optimism has been reignited surrounding Moderna's collaboration with Merck on a melanoma vaccine program, with encouraging data releases contributing to the stock's upward movement.
• Investor sentiment may have been bolstered by insider activities, including the exercising of RSUs by the company's President and CFO, signaling confidence in Moderna's future growth prospects.
• Anticipation is high due to Moderna's upcoming involvement in key healthcare conferences and the unveiling of promising data related to its melanoma treatment, which has further stimulated investor interest and pushed the stock price up.

04.05.2026 - MRNA Stock was up 5.0%

• The positive outlook on Moderna's future, particularly in mRNA technology and vaccine advancements, likely drove the stock's bullish trajectory.
• A recent SEC filing suggesting a share sale by an individual may have been perceived as a routine financial action, minimally impacting the market movement.
• In contrast to Ultragenyx (RARE) facing stock declines post-disappointing earnings, Moderna's robust market performance signals strong investor confidence in its growth potential and continued success.
• Market optimism stemming from reports of Deutsche Bank's increased price target for Star Bulk Carriers (SBLK) and potential in tech stocks may have bolstered overall positive sentiment, positively influencing Moderna's stock.

05.05.2026 - MRNA Stock was down 5.3%

• Moderna (MRNA) stock declined amid profit-taking following recent positive data on its personalized mRNA-based cancer vaccine.
• An individual's proposed sale of 3471 shares via an SEC filing potentially influenced the stock's downward trend.
• Despite encouraging updates on its cancer vaccine and past successful trials, investor response may have been dampened by the insider selling activity.
• The combination of profit-taking, insider selling, and general market sentiment likely contributed to Moderna's bearish performance today.

29.04.2026 - MRNA Stock was up 5.1%

• Moderna's bullish movement today can be attributed to the positive sentiment surrounding its innovative mRNA technology and ongoing developments in the healthcare sector.
• The FDA advisory panel's recommendation to update COVID-19 vaccines for the XFG variant for the 2026-27 season could have boosted investor confidence in Moderna's capabilities to adapt to evolving virus strains.
• Despite insider selling and a cautious Wall Street sentiment, the potential for premium pricing and accelerated global market access for Moderna's plant-based drug targeting BPH and prostate cancer prevention could have sparked investor optimism.
• The acquisition of shares by institutional investors like Seven Grand Managers LLC further indicates confidence in Moderna's long-term growth prospects, potentially contributing to the bullish movement.

28.04.2026 - MRNA Stock was down 5.2%

• The bearish movement in Moderna's stock today can be attributed to:
• Perceived overbought conditions and technical indicators signaling reversals, leading traders to take short positions.
• Concerns about the stock being fundamentally overvalued, especially after its recent inclusion in the S&P 500 index.
• Lack of significant positive news catalysts to sustain the recent bullish momentum.
• Despite the bearish movement, the upcoming FDA advisory committee review for Moderna's mRNA flu shot and the company's preparations for a COVID-19 booster vaccine targeting the XFG strain in 2026–27 could potentially drive positive sentiment and future price movements.

09.05.2026 - MRNA Stock was down 5.0%

• The authorization granted to Moderna and the University of Oxford to initiate a Phase 1/2 study on an mRNA cancer vaccine for individuals with Lynch syndrome did not appear to have a positive impact on the stock price. This lack of significant effect might suggest that investors were anticipating more substantial news to influence the market.
• The selling of shares by Moderna's Chief Legal Officer, Shannon Thyme Klinger, could have contributed to the negative market sentiment. This insider trading activity might have been perceived as a signal of uncertainty regarding the company's future outlook.
• Despite noteworthy advancements in cancer vaccine trials and the appointment of a seasoned professional from Procter & Gamble to Eikon Therapeutics' Board of Directors, the focus on the Chief Legal Officer's share selling could have overshadowed these developments. This focus possibly swayed the stock's downward trajectory.
• An analysis hinting at Moderna's stock being potentially overvalued by InvestingPro may have further fueled the bearish sentiment. This suggestion might have prompted investors to reassess their positions, potentially triggering a sell-off.

20.04.2026 - MRNA Stock was up 5.1%

• Moderna's stock surged by 20% due to emerging hantavirus cases, showcasing the market's confidence in the company's pandemic defense capabilities.
• The hantavirus scare not only boosted Moderna's stock but also highlighted the potential changes in vaccine-related regulatory environments, which could further benefit the company.
• Despite concerns about declining sales and profitability, Moderna's focus on infectious disease platforms and potential vaccine developments seems to have overshadowed these worries, driving the bullish movement in its stock today.

11.05.2026 - MRNA Stock was up 5.2%

• Recent investment by Nicollet Investment Management Inc. reflects strong confidence in Moderna's future, potentially influencing the stock price.
• The success of Parabilis Medicines' IPO and positive news about a new drug candidate may have positively impacted investor sentiment towards the biotech industry, which could benefit Moderna.
• Letko Brosseau & Associates Inc. selling some of their Moderna shares might indicate a strategic move to capitalize on past stock price gains.
• Comparisons between NVIDIA and GLOBALFOUNDRIES showcasing positive attitudes towards tech and biotech stocks could indirectly support Moderna's upward movement.